Cover Image
市場調查報告書

Sanofi Pasteur SA的產品平台分析

Sanofi Pasteur SA - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 251719
出版日期 內容資訊 英文 59 Pages
訂單完成後即時交付
價格
Back to Top
Sanofi Pasteur SA的產品平台分析 Sanofi Pasteur SA - Product Pipeline Review - 2016
出版日期: 2016年03月22日 內容資訊: 英文 59 Pages
簡介

Sanofi Pasteur SA總公司在法國的製藥企業,進行著細菌性及病毒性疾病疫苗的製造及銷售。產品利用於霍亂、白喉、b型流感感染疾病、腦膜炎感染疾病、百日咳、肺炎球菌、破傷風、結核、傷寒症、A型及B型肝炎、流感、麻疹、流行性腮腺炎、小兒麻庳病毒感染疾病、狂犬病(恐水症)的治療。

本報告提供Sanofi Pasteur SA 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Sanofi Pasteur SA 基本資料

  • Sanofi Pasteur SA 概要
  • 主要資訊
  • 企業資料

Sanofi Pasteur SA :R&D概要

  • 主要的治療範圍

Sanofi Pasteur SA :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Sanofi Pasteur SA :開發中產品概況

  • 後期階段產品開發中產品
    • 登記申請前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 在臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Sanofi Pasteur SA :藥物簡介

  • (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis + haemophilus influenza serogroup B) vaccine
  • clostridium difficile vaccine
  • dengue serotyoes 1, 2, 3,4 (tetravalent) vaccine
  • Rabies VRVg
  • Vaxigrip Quadrivalent
  • influenza vaccine (A/H7N9)
  • meningococcal polysaccharide + diphtheria vaccine serogroups A, C, Y and W-135
  • tuberculosis vaccine
  • EN41-FPA2
  • EN41-UGR7C
  • ETEC Adhesin-Based Vaccine
  • HSV-529
  • pneumococcal vaccine (trivalent)
  • streptococcus pneumonia vaccine
  • vCP-2292
  • Prophylactic Vaccine 2
  • vCP-2264
  • vCP-2291
  • universal influenza vaccine

Sanofi Pasteur SA :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Sanofi Pasteur SA :最近的開發平台資訊

Sanofi Pasteur SA :開發休止的計劃

Sanofi Pasteur SA :開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • Meningitis B Vaccine

Sanofi Pasteur SA :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07994CDB

Summary

Global Markets Direct's, 'Sanofi Pasteur SA - Product Pipeline Review - 2016', provides an overview of the Sanofi Pasteur SA's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sanofi Pasteur SA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Sanofi Pasteur SA
  • The report provides overview of Sanofi Pasteur SA including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Sanofi Pasteur SA's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Sanofi Pasteur SA's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Sanofi Pasteur SA's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sanofi Pasteur SA
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sanofi Pasteur SA's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Sanofi Pasteur SA Snapshot
    • Sanofi Pasteur SA Overview
    • Key Information
    • Key Facts
  • Sanofi Pasteur SA - Research and Development Overview
    • Key Therapeutic Areas
  • Sanofi Pasteur SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Sanofi Pasteur SA - Pipeline Products Glance
    • Sanofi Pasteur SA - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Sanofi Pasteur SA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Sanofi Pasteur SA - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • Sanofi Pasteur SA - Drug Profiles
    • dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [serotypes A, B] (split virion, tetravalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis (acellular)) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Clostridium difficile vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ETEC vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rabies [strain Wistar PM/WI 38-1503-3M] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tuberculosis vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VCP-2438
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HSV-529
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pneumococcal (trivalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Streptococcus pneumonia vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VCP-2292
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • infectious disease vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Sanofi Pasteur SA - Pipeline Analysis
    • Sanofi Pasteur SA - Pipeline Products by Target
    • Sanofi Pasteur SA - Pipeline Products by Route of Administration
    • Sanofi Pasteur SA - Pipeline Products by Molecule Type
  • Sanofi Pasteur SA - Recent Pipeline Updates
  • Sanofi Pasteur SA - Dormant Projects
  • Sanofi Pasteur SA - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • meningitis [serotype B] vaccine
  • Sanofi Pasteur SA - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Sanofi Pasteur SA, Key Information
  • Sanofi Pasteur SA, Key Facts
  • Sanofi Pasteur SA - Pipeline by Indication, 2016
  • Sanofi Pasteur SA - Pipeline by Stage of Development, 2016
  • Sanofi Pasteur SA - Monotherapy Products in Pipeline, 2016
  • Sanofi Pasteur SA - Combination Treatment Modalities in Pipeline, 2016
  • Sanofi Pasteur SA - Partnered Products in Pipeline, 2016
  • Sanofi Pasteur SA - Partnered Products/ Combination Treatment Modalities, 2016
  • Sanofi Pasteur SA - Pre-Registration, 2016
  • Sanofi Pasteur SA - Filing rejected/Withdrawn, 2016
  • Sanofi Pasteur SA - Phase III, 2016
  • Sanofi Pasteur SA - Phase II, 2016
  • Sanofi Pasteur SA - Phase I, 2016
  • Sanofi Pasteur SA - Discovery, 2016
  • Sanofi Pasteur SA - Pipeline by Target, 2016
  • Sanofi Pasteur SA - Pipeline by Route of Administration, 2016
  • Sanofi Pasteur SA - Pipeline by Molecule Type, 2016
  • Sanofi Pasteur SA - Recent Pipeline Updates, 2016
  • Sanofi Pasteur SA - Dormant Developmental Projects,2016
  • Sanofi Pasteur SA - Discontinued Pipeline Products, 2016
  • Sanofi Pasteur SA, Other Locations
  • Sanofi Pasteur SA, Subsidiaries

List of Figures

  • Sanofi Pasteur SA - Pipeline by Top 10 Indication, 2016
  • Sanofi Pasteur SA - Pipeline by Stage of Development, 2016
  • Sanofi Pasteur SA - Monotherapy Products in Pipeline, 2016
  • Sanofi Pasteur SA - Combination Treatment Modalities in Pipeline, 2016
  • Sanofi Pasteur SA - Partnered Products in Pipeline, 2016
  • Sanofi Pasteur SA - Pipeline by Target, 2016
  • Sanofi Pasteur SA - Pipeline by Route of Administration, 2016
  • Sanofi Pasteur SA - Pipeline by Molecule Type, 2016
Back to Top